CSIMarket Company Name, Ticker, Industry, else..


Absci Corp  (NASDAQ: ABSI)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare


 

Absci Corp

ABSI's Financial Statements and Analysis



Absci Corp narrowed forth quarter of 2024 net loss per share of $-0.21 compare to net loss per share of $-0.25 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.24 realized in previous quarter.


forth quarter of 2024
Earnings Per Share Revenues
$ -0.21 $  1 Mill
$+0.04     Unch.     +96.75 %



Absci's Revenue rose by 96.75 % in forth quarter of 2024 (Dec 31 2024) year on year, to $1 million and declined by -60.91 % sequentially.


Absci is

More on ABSI's Income Statement



Absci in the forth quarter of 2024 recorded net loss of $-28.983 million, an increase from net loss of $-23.545 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on ABSI's Growth

Absci Inventories
ABSI's Cash flow In the forth quarter of 2024 company's net cash flow was $3 million, capital expenditures fell by -0.01735.29%, to $0 millions compare to same quarter a year ago

More on ABSI's Cash flow Statement


Absci Corp does not pay out common stock dividend.

In trailing twelve-month period Absci Corp payed $ -0.66 cash per share, on a free-cash flow basis .

Book value fell by -7.84 % sequentially to $1.63 per share, -15.57% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.22 per share from $ 1.37.

Company repurchased 3.93 million shares or 3.46 % in Dec 31 2024.


• More on ABSI's Dividends

 Market Capitalization (Millions) 321
 Shares Outstanding (Millions) 110
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 157




Absci Corp does not pay out common stock dividend.

In trailing twelve-month period Absci Corp had negative $ -0.66 cash flow per share, on a free-cash flow basis .

Book value fell by -7.84 % sequentially to $1.63 per share, -15.57% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.22 per share from $ 1.37.

Company repurchased 3.93 million shares or 3.46 % in Dec 31 2024.


• More on ABSI's Balance Sheets

 Market Capitalization (Millions) 321
 Shares Outstanding (Millions) 110
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 157
   


  News about Absci Corp Earnings

Mysterious Decline: Absci Corp's Revenue Plummets in Fiscal Q3 2024

Absci Corporation, a data-first generative AI drug creation company, recently reported its financial results for the fiscal period of January to March ...

Absci Corp Takes a Financial Hit: Revenue Plummets by 78% in Fourth Quarter

Investors Beware: ABSI Reports Disastrous Fourth Quarter of 2023 Financial Results
Absci Corp (Nasdaq: ABSI) recently released its fourth quarter of 2023 financial report, and the numbers are painting a bleak picture for the company. Revenue took a nosedive, fading by a staggering -78.292% to just $0.34 million, while the net loss per share swelled to $-0.25, compared to $-0.24 in the previous reporting season. Additionally, revenue tumbled sequentially by -54.57% from the preceding quarter, dropping from $0.74 million.
The fourth quarter of 2023 earnings season saw Absci Corp realize a net loss of $-23.545 million, a significant increase from $-19.471 million in the same period a year ago. The compa...

Absci Corp Shows Remarkable Turnaround, Slashes Losses During 2023 Q3 Earnings Season

Absci Corp: A Closer Look at the Third Quarter Earnings Report
Absci Corp, a generative AI drug c...

Absci Corp Defies Market Trends with 236% Revenue Growth in Latest Fiscal Period, Despite Share Price Decline

Durin...

Absci Corp Delivers Impressive Financial Results with Revenue Surge of 54.945% in Q1 2023

Absci Corp, a company that specializes in synthetic biology, reported their financial results for the January to March 31 2023 interval. The company experienced a loss of $-0.26 per share in that interval, which is an improvement from the loss of $-0.33 per share experienced in the same financial reporting period a year prior. However, the company's shortfall increased from $-0.18 per share from the prior financial reporting period.
Although the company experienced a loss, their revenue inched up, showing signs of growth. The company recorded a strong 54.945% increase in revenue, with $1.27 million generated in the interval compared to the $0.82 million generated in the same interval a year prior. Howeve...


Date modified: 2025-03-19T16:21:47+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com